MEDPHARM LIMITED

• ⚠

  Annual accounts overdue

  Due 2025-12-31.

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -39.5%

  £18,676,309 → £11,296,451

• Cash

  -41%

  £976,583 → £576,116

• Net assets

  -1,132.8%

  £609,315 → -£6,292,978

• Employees

  -18.3%

  115 → 94

• Operating profit

  -29.6%

  -£5,356,901 → -£6,945,218

• Profit before tax

  -29.6%

  -£5,355,631 → -£6,940,548

• Wages

  -18.4%

  £4,440,757 → £3,624,691

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. MEDPHARM LIMITED 1999-09-13 → present
2. MEDFARM LIMITED 1999-09-03 → 1999-09-13
3. SUPA CONSULTING LIMITED 1999-06-07 → 1999-09-03

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

MHA Audit Services LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“All such things taken into consideration allows the directors to conclude that, the company shall have the necessary liquidity to conduct normal operations through a date twelve months beyond the date of these financial statements.”

Group structure

1. MEDPHARM LIMITED · parent
   1. MP Pharma Services Inc. 100% · Durham, NC 27703

Significant events

• “Revenue declined from £18.7m in 2022 to £11.3m in 2023, however the pipeline for future revenue remains strong.”
• “During the prior year (2022), progress was made in an agreement to sell the company, incurring costs of £243,915, but the transaction was ultimately abandoned.”
• “In 2024, the wider group undertook multiple refinancing transactions to fund operations and merged with Tergus Pharma Inc., a US-based CDMO.”
• “In January 2024, the parent company was refinanced, issuing Series A Preferred Shares, which retired third-party bank debt and provided operating funding to Medpharm Limited.”
• “In April 2025, the parent company was recapitalised, including incremental equity financing of US$11.9 million and restructuring debt obligations from the June 2024 merger with Tergus.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

13

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.